What is Syncromune?
Syncromune operates as a clinical-stage biopharmaceutical entity focused on the development of in situ platform therapies. By leveraging its proprietary SYNC-T technology, the company aims to transform the treatment landscape for metastatic solid tumors. The platform integrates partial tumor oncolysis with multi-target biologic agents to overcome systemic immunosuppression. Currently, the organization is advancing its lead candidates, SV-101 and SV-102, through Phase 1 clinical trials, aiming to elicit robust T-cell activation and durable immune memory. This methodology represents a sophisticated shift toward personalized, systemic cancer immunotherapy that seeks to improve patient survival rates significantly.
How much funding has Syncromune raised?
Syncromune has raised a total of $100M across 1 funding round:
Series A
$100M
Series A (2024): $100M, investors not publicly disclosed
Key Investors in Syncromune
Syncromune
Undisclosed investor participating in the funding round.
What's next for Syncromune?
Following this major enterprise-level funding, Syncromune is expected to prioritize the expansion of its clinical trial infrastructure and the acceleration of its lead assets. The capital will likely be deployed to scale manufacturing capabilities for its personalized therapy and to support the rigorous data collection required for subsequent trial phases. As the company moves deeper into its clinical roadmap, the focus will remain on validating the efficacy of the SYNC-T platform in diverse patient populations. Strategic milestones will include the publication of Phase 1 data and the potential initiation of expanded study cohorts, positioning the firm as a high-value player in the competitive oncology biotech market.
See full Syncromune company page
